JP4880477B2 - 胃粘膜疾患の治療のための医薬組成物 - Google Patents
胃粘膜疾患の治療のための医薬組成物 Download PDFInfo
- Publication number
- JP4880477B2 JP4880477B2 JP2006542160A JP2006542160A JP4880477B2 JP 4880477 B2 JP4880477 B2 JP 4880477B2 JP 2006542160 A JP2006542160 A JP 2006542160A JP 2006542160 A JP2006542160 A JP 2006542160A JP 4880477 B2 JP4880477 B2 JP 4880477B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- glutamine
- helicobacter pylori
- infected
- gastric mucosal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002496 gastric effect Effects 0.000 title claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- 201000010099 disease Diseases 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 37
- 229930182816 L-glutamine Natural products 0.000 claims description 32
- 241000590002 Helicobacter pylori Species 0.000 claims description 29
- 229940037467 helicobacter pylori Drugs 0.000 claims description 28
- VIZXMHCBZLGUET-UHFFFAOYSA-N sodium gualenate Chemical compound CC(C)C1=CC=C(C)C2=C(S(O)(=O)=O)C=C(C)C2=C1 VIZXMHCBZLGUET-UHFFFAOYSA-N 0.000 claims description 21
- 229950002760 sodium gualenate Drugs 0.000 claims description 20
- 235000005911 diet Nutrition 0.000 description 19
- 230000037213 diet Effects 0.000 description 19
- 241000699694 Gerbillinae Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 210000001156 gastric mucosa Anatomy 0.000 description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 description 8
- 206010017758 gastric cancer Diseases 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 201000011549 stomach cancer Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010019375 Helicobacter infections Diseases 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 229960002350 guaiazulen Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 2
- 240000008168 Ficus benjamina Species 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 150000001621 bismuth Chemical class 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229950005370 egualen Drugs 0.000 description 1
- KXGWXVVNYQOMQZ-UHFFFAOYSA-M egualen sodium Chemical compound [Na+].C1=C(C(C)C)C=CC=C2C(CC)=CC(S([O-])(=O)=O)=C21 KXGWXVVNYQOMQZ-UHFFFAOYSA-M 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
すなわち、本発明は、ヘリコバクター・ピロリ菌による胃粘膜疾患を治療するために使用する医薬組成物であって、L−グルタミンとグアイアズレンスルホン酸ナトリウムとを10:1から500:1までの比率で含有することを特徴とする医薬組成物である。
A群:ヘリコバクター・ピロリ菌に感染させていないスナネズミに、薬物を配合しない食餌を経口摂取させた(正常対照群)。
B群:ヘリコバクター・ピロリ菌に感染させていないスナネズミに、L−グルタミンが20(w/w)%含有する食餌を経口摂取させた。
C群:ヘリコバクター・ピロリ菌に感染させていないスナネズミに、L−グルタミンとグアイアズレンスルホン酸ナトリウムが予め330:1になるよう調整した薬物を20(w/w)%含有する食餌を経口摂取させた。
D群:ヘリコバクター・ピロリ菌を感染させたスナネズミに、薬物を配合しない食餌を経口摂取させた(対照群)。
E群:ヘリコバクター・ピロリ菌を感染させたスナネズミに、L−グルタミンが2(w/w)%含有する食餌を経口摂取させた。
F群:ヘリコバクター・ピロリ菌を感染させたスナネズミに、L−グルタミンが10(w/w)%含有する食餌を経口摂取させた。
G群:ヘリコバクター・ピロリ菌を感染させたスナネズミに、L−グルタミンが20(w/w)%含有する食餌を経口摂取させた。
H群:ヘリコバクター・ピロリ菌を感染させたスナネズミに、L−グルタミンとグアイアズレンスルホン酸ナトリウムが予め330:1になるよう調整した薬物を2(w/w)%含有する食餌を経口摂取させた。
I群:ヘリコバクター・ピロリ菌を感染させたスナネズミに、L−グルタミンとグアイアズレンスルホン酸ナトリウムが予め330:1になるよう調整した薬物を10(w/w)%含有する食餌を経口摂取させた。
J群;ヘリコバクター・ピロリ菌を感染させたスナネズミに、L−グルタミンとグアイアズレンスルホン酸ナトリウムが予め330:1になるよう調整した薬物を20(w/w)%含有する食餌を経口摂取させた。
第1図は、A〜Jの各群について、胃粘膜病変(潰瘍、うっ血、浮腫及び粘膜損傷)の程度を面積(mm2)で示したグラフである。
第2図は、A〜Jの各群について、胃粘膜湿重量(mg)を示したグラフである。
第3図は、A〜D,G,J群について、胃粘膜に発生した腫瘍(胃癌様病変)の程度を面積(mm2)で示したグラフである。
各図において*印は、D群に対する、ダネット検定におけるP値が5%未満であって、統計的に有意差があることを示す。
Claims (1)
- ヘリコバクター・ピロリ菌による胃粘膜疾患を治療するために使用する医薬組成物であって、L−グルタミンとグアイアズレンスルホン酸ナトリウムとを10:1から500:1までの比率で含有することを特徴とする医薬組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/015860 WO2006043336A1 (ja) | 2004-10-20 | 2004-10-20 | 胃粘膜疾患の治療又は予防のための組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006043336A1 JPWO2006043336A1 (ja) | 2008-05-22 |
JP4880477B2 true JP4880477B2 (ja) | 2012-02-22 |
Family
ID=36202762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006542160A Active JP4880477B2 (ja) | 2004-10-20 | 2004-10-20 | 胃粘膜疾患の治療のための医薬組成物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4880477B2 (ja) |
CN (1) | CN101065121A (ja) |
WO (1) | WO2006043336A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0602446L (sv) * | 2006-11-16 | 2008-05-17 | Entress Ab | Ny användning av kända farmakologiskt aktiva kemiska sammansättningar |
WO2008123298A1 (ja) | 2007-03-26 | 2008-10-16 | Hirofumi Matsui | 癌患者用輸液製剤 |
CN104825433A (zh) * | 2007-07-03 | 2015-08-12 | 达努塔·克鲁谢夫斯卡 | α-酮戊二酸的新医药用途 |
JP5465867B2 (ja) * | 2008-11-12 | 2014-04-09 | 壽製薬株式会社 | 安定なエグアレンナトリウム固形製剤 |
CN102861337B (zh) * | 2012-03-26 | 2017-08-11 | 北京阜康仁生物制药科技有限公司 | 一种含乙呱仑钠固体制剂 |
CN106901344A (zh) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | 一种缓解胃痛腹痛的组合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6048960A (ja) * | 1983-08-24 | 1985-03-16 | Kotobuki Seiyaku Kk | アズレン誘導体及びその製法並びにこの化合物を有効成分とする抗潰瘍剤 |
JPS6314719A (ja) * | 1986-07-08 | 1988-01-21 | Shunichi Naito | グアヤズレンスルホン酸塩製剤 |
US20010031748A1 (en) * | 1996-10-11 | 2001-10-18 | Thompson Richard Paul Hepworth | Use of metal complexes to treat gastrointestinal infections |
JP2003160484A (ja) * | 2001-11-27 | 2003-06-03 | Kotobuki Seiyaku Kk | 苦味軽減した経口投与製剤組成物 |
JP2004002320A (ja) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | 生体内で相転移する液状マトリックスおよび液状経口製剤 |
-
2004
- 2004-10-20 JP JP2006542160A patent/JP4880477B2/ja active Active
- 2004-10-20 WO PCT/JP2004/015860 patent/WO2006043336A1/ja active Application Filing
- 2004-10-20 CN CNA2004800442637A patent/CN101065121A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6048960A (ja) * | 1983-08-24 | 1985-03-16 | Kotobuki Seiyaku Kk | アズレン誘導体及びその製法並びにこの化合物を有効成分とする抗潰瘍剤 |
JPS6314719A (ja) * | 1986-07-08 | 1988-01-21 | Shunichi Naito | グアヤズレンスルホン酸塩製剤 |
US20010031748A1 (en) * | 1996-10-11 | 2001-10-18 | Thompson Richard Paul Hepworth | Use of metal complexes to treat gastrointestinal infections |
JP2003160484A (ja) * | 2001-11-27 | 2003-06-03 | Kotobuki Seiyaku Kk | 苦味軽減した経口投与製剤組成物 |
JP2004002320A (ja) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | 生体内で相転移する液状マトリックスおよび液状経口製剤 |
Also Published As
Publication number | Publication date |
---|---|
CN101065121A (zh) | 2007-10-31 |
WO2006043336A1 (ja) | 2006-04-27 |
JPWO2006043336A1 (ja) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4880477B2 (ja) | 胃粘膜疾患の治療のための医薬組成物 | |
JP6444515B2 (ja) | タウリンのコロナウイルス属及び/又はロタウイルス属のウィルスにより引き起こされる疾患の予防及び/又は治療における応用 | |
US11026906B2 (en) | Pharmaceutical quality strontium L-lactate | |
JP2022537712A (ja) | 代謝性肝疾患の予防または治療用組成物 | |
JPWO2014010658A1 (ja) | ヒハツ配合製剤 | |
AU2013320148B2 (en) | Plant phenols and their use in the treatment or prevention of eosinophilic esophagitis | |
EP2870964A2 (en) | Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same | |
JP2015193660A (ja) | 経口b12治療 | |
JP4667244B2 (ja) | 医薬組成物 | |
WO2012106947A1 (zh) | 含维生素d和二甲双胍的药物组合物 | |
JP4203170B2 (ja) | 医薬組成物 | |
JP4786166B2 (ja) | 制酸剤組成物 | |
US20080145409A1 (en) | Composition for the treatment and prevention of peptic ulcer | |
KR102405111B1 (ko) | 쇼가올을 이용한 철 항상성 유지 방법 | |
JP7293492B2 (ja) | 尿酸性疾患を予防又は治療するための組成物 | |
TWI846645B (zh) | 光色素用於製備治療或改善非酒精性脂肪性肝病及肥胖症之組合物的用途 | |
CN112933091B (zh) | 一种抗胃酸类疾病的药物组合物及应用 | |
KR20070073894A (ko) | 위 점막 질환의 치료 또는 예방을 위한 조성물 | |
DK2537528T3 (en) | Pharmaceutical compositions containing beta and alpha-galactosidase and their use in the treatment of gastroesophageal reflux disease | |
JP4993998B2 (ja) | イブプロフェンを含有する医薬組成物 | |
EP4393486A1 (en) | Compositions and methods for preventing or reducing the risk of metabolic syndrome | |
JP2007145731A (ja) | 止瀉効果を有する内服用製剤 | |
JPWO2008136173A1 (ja) | スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤 | |
JP2007137896A (ja) | イブプロフェン含有医薬製剤 | |
CN115531444A (zh) | 预防/治疗猫结石症的药物组合物和制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070802 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110318 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111108 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111201 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4880477 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141209 Year of fee payment: 3 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141209 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |